The first in a new class of treatment in Europe

Ryeqo is a GnRH antagonist combined with add-back therapy
in a single, once-daily pill1
Ryeqo is indicated in adult women of reproductive age for:1
  • Treatment of moderate to severe symptoms of uterine fibroids

  • Symptomatic treatment of
    endometriosis in women with a history
    of previous medical or surgical
    treatment for their endometriosis

How Ryeqo works

Designed to delicately balance efficacy and safety.1,2

Relugolix drives improvements in uterine fibroids and endometriosis symptoms while add-back therapy minimises effects typical of hypoestrogenic states, providing the right balance between efficacy and safety.2–7

Adapted from Donnez et al. 2021.8
Adapted from Giudice et al. 2022.2